Progress on pulmonary vasodilator drugs in the treatment of bronchopulmonary dysplasia-associated pulmonary hypertension
10.3760/cma.j.issn.1673-4912.2024.05.008
- VernacularTitle:肺血管扩张药物治疗支气管肺发育不良相关性肺动脉高压的研究进展
- Author:
Xiaoting BAI
1
;
Hua MEI
Author Information
1. 内蒙古医科大学附属医院新生儿科，呼和浩特 010050
- Keywords:
Pulmonary vasodilator medications;
Pulmonary hypertension;
Bronchopulmonary dysplasia;
Preterm
- From:
Chinese Pediatric Emergency Medicine
2024;31(5):358-362
- CountryChina
- Language:Chinese
-
Abstract:
Bronchopulmonary dysplasia is the most common chronic lung disease in very preterm infants.Some severe bronchopulmonary dysplasia is often combined with pulmonary hypertension，characterized by diffuse alveolar damage and abnormal pulmonary vascular remodeling，followed by right heart failure due to increased pulmonary vascular resistance.It seriously affects the physical and neurological development of preterm infants.Pulmonary vasodilator drugs can reduce pulmonary artery pressure through nitric oxide pathway，endothelin pathway and prostaglandin pathway.This review summarized the pulmonary vasodilator drugs in the treatment of pulmonary hypertension associated with bronchopulmonary dysplasia.
